Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease by Xinxia Chang et al.
Chang et al. J Transl Med  (2016) 14:266 
DOI 10.1186/s12967-016-0982-x
RESEARCH
Lipid profiling of the therapeutic effects 
of berberine in patients with nonalcoholic fatty 
liver disease
Xinxia Chang1,2, Zhe Wang3, Jinlan Zhang3, Hongmei Yan1,2, Hua Bian1,2, Mingfeng Xia1,2, Huandong Lin1,2, 
Jiandong Jiang3* and Xin Gao1,2*
Abstract 
Background: We recently demonstrated a positive effect of berberine on nonalcoholic fatty liver disease patients 
after 16 weeks of treatment by comparing mere lifestyle intervention in type 2 diabetes patients with berberine 
treatment, which decreased the content of hepatic fat. However, the potential mechanisms of the clinical effects are 
unclear. We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of 
subjects with nonalcoholic fatty liver disease (NAFLD) before and after berberine treatment.
Methods: Liquid chromatography–mass spectrometry evaluated the various lipid metabolites in serum samples 
obtained from the participants (41 patients in the berberine group and 39 patients in the mere lifestyle intervention 
group) before and after treatment.
Results: A total of 256 serum lipid molecular species were identified and quantified. Both treatments regulated vari-
ous types of lipids in metabolic pathways, such as free fatty acids, phosphoglycerides and glycerides, in metabolic 
pathways, but berberine induced a substantially greater change in serum lipid species compared with mere lifestyle 
intervention after treatment. Berberine also caused obvious differences on ceramides. Berberine treatment markedly 
decreased serum levels of ceramide and ceramide-1-phosphate.
Conclusions: Berberine altered circulating ceramides, which may underlie the improvement in fatty liver disease.
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Background
Berberine (BBR) is an alkaloid that was originally isolated 
from Huanglian (Coptischinensis). BBR is used as anti-
microbial in China. Recent studies have demonstrated 
beneficial effects of BBR on serum lipids and glucose 
metabolism [1–3]. BBR exerted an anti-hyperlipidemia 
effect of lowering total cholesterol (TC), triglyceride 
(TG), low-density lipoprotein cholesterol (LDL-c) levels 
in patients [2]. The cholesterol-lowering mechanism of 
BBR was different from that of statins. Berberine elevated 
the LDLR expression by stabilizing LDLR message ribo-
nucleic acid(mRNA) [2] and blocking proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) transcription [4, 
5], but statins upregulated PSCK9 gene expression [6]. 
BBR is also an effective anti-diabetes agent.BBR signifi-
cantly lowered fasting blood glucose (FBG), hemoglobin 
A1C, triglyceride, and insulin levels in patients with type 
2 diabetes mellitus (T2DM) in the clinical study [7].
The liver plays a vital role in lipid metabolism and 
glucose homeostasis. Nonalcoholic fatty liver disease 
(NAFLD) is associated with insulin resistance and the 
development of type 2 diabetes [8]. The effect of BBR on 
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that BBR played a central role in decreasing hepatic fat 
content. Our previous study [9] demonstrated that BBR 
decreased hepatic fat content by 57.2  %, and reduced 
serum lipids and liver enzymes, which indirectly indi-
cated that BBR improved liver inflammation. However, 
the mechanism of reducing hepatic fat content is not 
known.
Increased TG accumulation in the liver is the patho-
physiological hallmark of NAFLD. Some studies suggest 
that the lipid metabolism perturbations in NAFLD are 
more complex. A comprehensive lipidomics study dem-
onstrated that substantial changes in other lipid classes, 
such as cholesterol and specific phospholipids in the liver 
may play a role in the pathogenesis of NAFLD and the 
development of NASH [10]. NAFLD is also associated 
with several changes in circulating lipidomics, such as an 
increase in the ratio of monounsaturated fatty acids: vs 
saturated fatty acids and a significant decrease in circu-
lating levels of the essential fatty acids linoleic acid (18:2 
n6) and alpha-linolenic acid (18:3 n3) across multiple 
lipid classes. The lipogenic activity levels off or declines 
modestly with progression to nonalcoholic steatohepa-
titis (NASH), but lipoxygenase (LOX) activity increases 
[11]. Therefore, circulating lipidomics are closely asso-
ciated with fat deposits in hepatocytes. Whether the 
compositions of the lipids are harmful and whether the 
changes of serum lipidomics are related with berberine 
treatment effect are not well identified. This study used 
a comprehensive lipidomic approach: (1) to quantify the 
absolute and relative amounts of free fattyacids (FFAs), 
glycerolipids (GL), glycerophospholipids (GP) and sphin-
golipids (SP) in subjects with NAFLD before and after 
berberine treatment and lifestyle intervention and (2) 
to compare the distribution of fatty acids within each of 
these classes in these groups of subjects.
Methods
Participants
The detailed design of this study was previously published 
[9]. Briefly, a randomized, parallel-controlled, open-label 
clinical trial was conducted in three medical centers for 
the treatment of NAFLD patients with impaired glucose 
regulation (IGR) or T2DM with lifestyle intervention 
(LSI) with or without BBR (NIH Registration number: 
NCT00633282). The trial design conformed to the revised 
CONSORT standards for the reporting of randomized 
trials. Eligible adults were identified and recruited from 
unsolicited referrals to the three participating clinical 
centers from March 2008 to August 2011. Hepatic fat con-
tent (HFC) was assessed using proton magnetic resonance 
spectroscopy (1H MRS). Subjects who met all enrollment 
criteria were randomly assigned to one of the two groups 
for the 16-week clinical trial, Group A- LSI or Group 
B-LSI plus BBR (0.5  g, t.i.d.). BBR (berberine®, Huashi 
Pharmaceuticals Shanghai, China, Inc.) was administered 
orally at a 0.5  g dose 30  min before meals, three times 
daily (according to the Chinese Pharmacopeia [12]. LSI 
(including dietary modification and exercise) was per-
formed following standardized recommendations [13]. All 
participants were required to fast overnight (12 h) before 
participating in a physical examination by trained staff 
and physicians using standard protocols. Blood samples 
were drawn after an overnight fast and immediately cen-
trifuged. The samples were frozen immediately and stored 
at −80 °C until assayed. These samples were used for the 
final lipidomics analysis. Table 1 summarizes the detailed 
characteristics of these 80 patients at baseline and at the 
end of follow-up. The following main reasons determined 
the exclusion of the original participants from the pre-
sent analysis: (1) incomplete information and (2) insuffi-
cient blood samples. The ethics committee of Zhongshan 
Hospital, Fudan University approved the study, which 
was conducted in accordance with the guidelines of the 
Declaration of Helsinki. Written informed consent was 
obtained from each patient.
Materials
All lipid standards were purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). Organic residue grade 
methanol, MS grade acetonitrile and HPLC grade 
methyl-tert-butyl ether (MTBE) were purchased from 
Mallinckrodt BakerInc. (Phillipsburg, NJ, USA). HPLC 
grade isopropyl alcohol and chloroform were purchased 
from Honeywell Inc. (Muskegon, MI, USA). Formic acid 
of analytical grade was obtained from TEDIA Com-
pany, Inc. (Fairfield, OH, USA). Ammonium formate and 
ammonium acetate (purity 99.99 %) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Ultra-pure water 
was prepared using a Milli-Q purification system (Milli-
pore, Bedford, MA, USA).
Method of lipid profiling
Free fatty acids were determined according to our previ-
ous study [14]. Samples were first extracted using reverse 
phase SPE and analyzed in an Agilent 6410B Triple 
Quadrupole LC–MS after pre-column derivatization.
Sphingolipids, phosphoglycerides and glycerides were 
determined in our lipid profiling platform [15] with a 
slight modification Plasma (0.1  mL) was transferred 
into a glass tube containing 20 μL of sphingolipid inter-
nal standards. Methanol (1.5 mL) was added to the tube, 
and the sample was vortexed for 10 s. Methyl-tert-butyl 
ether (MTBE) (5  mL) was added, and the sample was 
vortexed again for 15 min. Phase separation was induced 
by the addition of 1.5  mL of MS-grade water. Sam-
ples were incubated for 10  min at room temperature, 
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and the tube was centrifuged at 4500  r/min for 10 min. 
The organic supernatant was collected, and the lower 
phase was re-extracted with 2 mL of the solvent mixture 
(MTBE:methanol:water, 10:3:2.5). The pooled organic 
supernatant was collected and dried under a gentle 
nitrogen stream. The dried extracts were re-dissolved 
in 100  μL of methanol/chloroform (1:1, v/v) containing 
internal standards of phosphoglycerides, glycerides and 
sphingomyelins for analysis. A 50-μL aliquot was used 
for Agilent 6410B Triple Quadrupole LC–MS testing to 
analyzes phingolipids, and another 50  μL were used for 
Thermo Scientific HPLC-LTQ/FTICRMS testing to ana-
lyze phosphoglycerides, glycerides and sphingomyelins.
Chromatographic separation was performed for 
sphingolipids testing using a SpectraC8SR column 
(150 × 3.0 mm; 3 μm particle size; Peeke Scientific, Red-
wood City, CA, USA). The column temperature was 
40  °C. Mobile phase A was comprised of 1 mM ammo-
nium formate in water containing 0.1  % formic acid. 
Mobile phase B was comprised of 1  mM ammonium 
Table 1 Changes of clinical and biochemical parameters after treatment
The data were presented as the mean ± SD, except for skewed variables, which were presented as the median with the interquartile range given in parentheses
LSI lifestyle intervention, BBR plus LSI berberine treatment plus lifestyle intervention, BMI body-mass index, HFC hepatic fat content, TC total cholesterol, TG 
triglyceride, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT 
γ-glutamyltransferase
BBR plus LSI (n = 41) P value LSI (n = 39) P value
Baseline After 16 w Baseline After 16 w
Sex (M/F) 26/15 20/19
Age (years) 51.2 ± 9.4 50.8 ± 10.4
Weight (kg) 77.0 ± 15.4 72.8 ± 13.3 <0.01 75.9 ± 10.6 74.0 ± 11.1 <0.05
BMI (kg/m2) 27.4 ± 4.1 25.5 ± 3.3 <0.01 27.3 ± 3.0 26.0 ± 5.9 <0.05
Waist (cm) 94.5 ± 11.1 89.7 ± 9.7 <0.01 93.1 ± 7.3 90.8 ± 8.5 <0.05
HFC (%) 30.3 (22.2–44.0) 13.6 (9.3–17.4) <0.01 28.7 (21.9–46.8) 20.3 (11.3–33.0) <0.05
Blood glucose (mmol/L)
 0 min 6.4 ± 0.9 6.1 ± 1.3 <0.01 6.2 ± 1.0 6.2 ± 0.9 0.47
 30 min 11.1 ± 1.7 9.9 ± 1.9 <0.05 11.0 ± 1.7 10.4 ± 2.1 0.13
 60 min 13.1 ± 2.5 11.1 ± 2.6 <0.05 13.0 ± 2.6 11.9 ± 3.1 <0.05
 120 min 11.2 ± 3.0 8.6 ± 2.8 <0.05 10.8 ± 3.3 10.1 ± 2.9 0.14
 180 min 7.2 ± 2.3 5.4 ± 1.6 <0.05 6.5 ± 2.8 5.9 ± 2.3 <0.05
 AUCg 42.4 ± 7.6 36.3 ± 8.4 <0.05 41.2 ± 8.4 39.1 ± 9.3 <0.05
 HbA1c (%) 6.4 ± 0.7 6.0 ± 0.4 <0.01 6.3 ± 0.7 6.2 ± 0.7 0.11
Serum insulin (mU/mL)
 0 min 13.4 (8.5–16.2) 10.8 (8.5–14.1) 0.97 3.4 (8.6–18.6) 12.4 (7.1–19.1) 0.89
 30 min 41.0 (30.6–62.2) 47.9 (33.3–88.5) 0.34 59.9 (33.2–83.4) 54.2 (28.8–77.7) 0.28
 120 min 69.9 (47.5–100.9) 68.0 (41.2–103.1) 0.75 78.1 (57.1–132.7) 74.6 (45.7–117.9) 0.23
 HOMA-IR 3.6 (2.4–4.1) 2.8 (2.2–3.9) 0.21 3.7 (2.5–5.0) 3.4 (1.8–5.1) 0.32
 HOMAβ 88.2 (54.3–114.4) 93.1 (64.1–129.6) 0.12 97.7 (62.2–151.1) 100.0 (56.8–152.6) 0.69
 ΔI30/ΔG30 8.0 (4.1–13.6) 10.7 (5.3–20.3) P < 0.05 9.4 (5.0–16.6) 9.3 (3.6–18.6) 0.65
 TC (mmol/L) 5.3 ± 0.9 4.6 ± 1.0 P < 0.01 5.0 ± 0.8 5.0 ± 0.8 0.92
 TG (mmol/L) 2.2 ± 1.2 1.6 ± 0.9 P < 0.05 2.0 ± 0.8 1.9 ± 1.1 0.69
 HDL-c (mmol/L) 1.2 ± 0.2 1.2 ± 0.3 0.65 1.2 ± 0.3 1.2 ± 0.2 0.55
 LDL-c (mmol/L) 3.2 ± 0.9 3.0 ± 0.9 P < 0.05 3.0 ± 0.8 3.0 ± 0.8 0.73
 APO-A(g/L) 1.3 (1.1–1.4) 1.2 (1.0–1.3) P < 0.05 1.3 (1.0–1.4) 1.3 (1.1–1.5) 0.89
 APO-B(g/L) 1.0 ± 0.2 0.9 ± 0.2 P < 0.05 1.0 ± 0.2 1.0 ± 0.2 0.28
 APO-E (mg/L) 48.0 (37.0–57.3) 42.5 (36.0–49.7) 0.08 44.0 (37.9–52.3) 44.0 (38.5–56.5) 0.94
 LP(a) (mg/L) 104.0 (50.0–248.0) 101.0 (49.5–272.0) P < 0.05 155.0 (78.0–218.0) 160.0 (90.3–263.0) 0.23
Liver enzyme (U/L)
 ALT 36.0 (24.5–47.0) 21.0 (13.5–29.5) P < 0.01 34.0 (25.3–46.5) 21.0 (15.0–36.3) P < 0.01
 AST 25.0 (20.0–32.0) 19.0 (16.0–22.5) P < 0.01 25.0 (20.0–30.0) 20.5 (15.8–27.0) P < 0.05
 γ-GT 39.0 (26.0–67.5) 30.0 (23.0–43.0) P < 0.01 33.0 (22.0–56.5) 27.5 (20.5–48.8) P < 0.05
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formate in methanol containing 0.1  % formic acid. 
The gradient was programmed as follows: 0–10  min, 
80–100 % B; 10–18 min, 100 % B; 18–18.1 min, 100–80 % 
B; and 18.1–25 min, 80 % B. The flow rate was 0.5 mL/
min. The injection volume was 3 μL. The parameters for 
electrospray ionization tandem MS in positive ion mode 
were as follows: gas temperature, 350  °C; gas flow rate, 
10 L/min; nebulizer, 30 psi; and capillary voltage, 4000 V. 
Multiple reaction monitoring was performed using the 
characteristic precursor-to-production transitions, opti-
mized fragmentor voltages, and collision energies.
The surveyor HPLC system was equipped with an X 
terra MS C8 column (100 × 2.1 mm; 3.5-μm particle size; 
Waters, Milford, MA, USA) for phosphoglycerides, glyc-
erides and sphingomyelins testing. Mobile phase A was 
comprised of 0.1 % formic acid in water containing 2 mM 
ammonium acetate. Mobile phase B was comprised 
of 2-propanol/acetonitrile (2:5, v/v) containing 2  mM 
ammonium acetate and 0.1 % formic acid. The flow rate 
was 0.35  mL/min. The gradient was programmed con-
secutively as follows: 0–1 min, 10 % B; 1–2 min, 10–30 % 
B2-4  min, 30–50  % B; 4–8  min, 50–70  % B; 8–12  min, 
70–100  % B; and 12–24  min, 100  % B. The oven tem-
perature was 40 °C. The injection volume was 10 μL. The 
LTQ-FT was run in full-scan mode at 100,000 resolution 
ranging from m/z 50–1200 with the following MS param-
eters: sheath gas flow rate, 50  arb; aux gas flow rate, 
20 arb; sweep gas flow rate, 3 arb; and capillary tempera-
ture, 275 °C in positive and negative mode. The positive 
mode used a spray voltage of 4.5 kV, capillary voltage of 
35.0 V, and tube lens of 120 V. The negative mode used a 
spray voltage of −4.0 kV, capillary voltage of −35.0 V, and 
tube lens of −120 V.
Sphingolipids were identified based on retention time 
using authentic standards and quantified using standard 
curve samples. The identification and quantitation of 
other lipids was performed using the lipid data analyzer 
(LDA) software package (Graz University of Technology, 
Graz, Austria).
Statistical analysis
Variables are expressed as the means ±  SD or medians 
(quartile). Differences between groups were analyzed 
using Student’s t test (for data that were normally dis-
tributed) or the Mann–Whitney test (for data that were 
not normally distributed) using SPSS 18.0 software (SPSS 
Inc., Chicago, IL, USA). A P value less than 0.05 was 
considered significant. Orthogonal partial least squares 
discriminant analysis (OPLS-DA) was used to visually 
discriminate between groups. Lipid profiling data were 
mean-centered and Pareto-scaled using Simca P + 12.0.1 
(Umetrics, Umeå, Sweden) to reduce noise and artifacts. 
The quality and predictability of each OPLS-DA model 
was evaluated using R2Y (cum) and Q2 (cum) values, 
respectively. The following criteria for each potential bio-
marker were used: (1) A variable importance in projec-
tion greater than one; (2) The jack-knife uncertainty bar 
excluded zero; and (3) The absolute value of P corr in the 
S-plot was greater than 0.58 [16].
Results
The general characteristics of the subjects at baseline
Serum samples, which were subjected to the lipidomics 
analyses, were obtained from 41 BBR-treated patients and 39 
LSI patients at baseline and at the end of treatment. Table 1 
summarizes the detailed characteristics of the 80 patients at 
baseline. There were no significant differences in the clinical 
characteristics between groups at baseline, which suggests 
that the two groups were well matched in demographic pro-
files, HFC and other baseline characteristics (Table 1).
Berberine significantly influenced hepatic fat content 
and energy metabolism
After 16  w treatment, HFC decreased by 55.1  % in the 
BBR group (P  =  0.00) and by 29.3  % in the LSI group 
(P  <  0.05; Table  1). BBR caused a greater reduction in 
HFC as compared to that with LSI alone (P  =  0.021; 
Additional file 1: Table S1). Liver enzymes, such as ALT, 
AST and γ-GT were not significantly different between 
BBR and LSI groups at the 16th week (Additional file 1: 
Table S1).
Body weight, waist, body mass index (BMI), HFC, 
blood glucose, HbA1c, ΔI30/ΔG30, serum cholesterol, 
triglyceride, LDL-c, apoA/B, LP(a) and liver enzymes 
were significantly decreased after 16 weeks of BBR treat-
ment (P < 0.05) (Table 1). BBR exhibited greater decreases 
in body weight, BMI, waist, HFC, serum cholesterol and 
triglycerides compared with LSI alone (Additional file 1: 
Table S1), which demonstrates a clearly significant ben-
efit of BBR on metabolism. Additional file  2: Figure S1 
shows the line graph of the glucose tolerance test (0–3 h). 
BBR reduced the area under the OGTT curve [−5.9(−6.9 
to −4.8) vs. −4.0(−4.6 to −1.9), P =  0.041] more than 
lifestyle intervention alone.
Lipid profiling of berberine treatment and lifestyle 
intervention alone
Sixty-one free fatty acids, 54 sphingolipids, 86 phospho-
glycerides and 55 glycerides were successfully identified 
and quantified. Subsequent comprehensive statistical anal-
yses identified lipid variations between the groups. Table 2 
shows lipids with significant differences between groups 
after Student’s t test and Mann–Whitney tests. Figure  1 
shows the effect of berberine and lifestyle intervention on 
lipid metabolic pathways. Berberine altered lipid metabo-
lism, and this effect was related to a variety of lipid types.
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Table 2 Lipid items significantly changed in response to berberine treatment and lifestyle intervention
BBR plus LSI (n = 41) P value LSI (n = 39) P value
Baseline 16 w Baseline 16 w
Free fat acid
 FA(15:1) 3.5 ± 2.3 2.5 ± 1.5 0.029 3.1 ± 2.3 2.9 ± 3.0 0.689
 FA(16:1) 2.5 (1.5–3.5) 1.5 (1.1–2.4) 0.006 2.1 (1.3–3.5) 1.2 (0.9–2.4) 0.013
 FA(16:2) 1.6 (0.7–2.2) 0.7 (0.5–1.2) 0.008 1.1 (0.7–2.5) 0.6 (0.5–1.3) 0.028
 FA(16:3) 1.3 ± 1.0 0.9 ± 0.6 0.026 1.3 ± 1.2 1.1 ± 1.1 0.453
 FA(18:1) 2.7 (1.7–4.1) 2.0 (1.5–3.3) 0.043 2.4 (1.7–3.4) 1.6 (1.1–2.9) 0.054
 FA(18:2) 2.3 (1.3–3.6) 1.2 (0.8–1.8) 0.005 1.6 (1.1–3.0) 1.4 (0.8–1.7) 0.010
 FA(20:2) 2.4 (1.3–4.1) 1.7 (1.0–2.8) 0.024 1.9 (1.3–2.9) 1.4 (1.0–2.1) 0.028
 FA(20:3) 2.1 (1.3–4.3) 1.4 (0.9–2.1) 0.003 1.7 (1.3–3.3) 1.3 (1.0–1.9) 0.031
 FA(20:4) 1.6 (0.8–3.0) 0.8 (0.6–1.5) 0.005 1.2 (0.8–2.2) 0.9 (0.6–1.5) 0.081
 FA(20:5) 1.3 (0.6–3.3) 0.7 (0.4–1.21) 0.006 1.3 (0.7–3.3) 0.9 (0.5–2.2) 0.176
 FA(22:4) 2.8 ± 1.9 2.0 ± 1.6 0.038 2.7 ± 2.4 2.2 ± 1.8 0.294
 FA(22:5) 1.5 (0.9–2.4) 1.1 (0.7–1.7) 0.032 1.4 (1.0–2.0) 1.2 (0.9–1.8) 0.230
 FA(22:6) 1.3 (0.9–2.9) 1.0 (0.6–1.7) 0.017 1.3 (0.9–2.8) 1.1 (0.7–2.0) 0.101
  FA27 0.9 (0.6–1.6) 0.8 (0.5–1.3) 0.381 1.0 (0.7–1.6) 0.7 (0.5–1.1) 0.040
  FA3 1.0 (0.7–1.4) 0.6 (0.4–1.2) 0.018 1.1 (0.6–1.7) 0.8 (0.6–1.2) 0.057
  FA40 2.1 ± 1.6 1.4 ± 1.0 0.011 2.2 ± 1.9 1.8 ± 1.5 0.303
  FA48 2.2 (1.3–4.4) 1.4 (0.9–2.1) 0.020 1.8 (1.2–4.2) 1.2 (0.9–2.8) 0.072
  FA51 2.9 (2.01–4.8) 1.9 (1.3–3.0) 0.004 2.5 (1.6–3.6) 1.9 (1.4–2.6) 0.029
 FA(α-18:3) 1.9 (1.1–3.6) 1.0 (0.8–1.4) 0.003 1.8 (1.2–2.6) 1.0 (0.7–1.5) 0.002
 FA(γ-18:3) 1.7 (1.0–2.8) 0.9 (0.7–1.2) 0.001 1.3 (0.8–2.3) 0.9 (0.7–1.7) 0.842
Sphingolipid (pmol/ml)
 Sph(d18:1) 15.3 (6.1–38.1) 11.3 (4.7–22.8) 0.139 20.4 (7.1–35.5) 10.7 (4.8–19.0) 0.050
 Cer(d18:1/18:0) 41.1 (30.4–52.0) 31.8 (25.1–43.6) 0.033 37.7 (33.3–50.6) 34.8 (27.1–47.5) 0.576
 Cer(d18:1/18:0)-
1-p
472.4 (337.2–668.4) 423.6 (327.1–497.6) 0.033 491.5 (360.7–635.4) 459.8 (328.5–542.1) 0.734
 Cer(d18:1/20:0) 103.7 (67.0–121.5) 87.1 (67.3–103.1) 0.047 87.1 (80.9–109.3) 85.5 (72.9–104.0) 0.398
 Cer(d18:1/28:0)-
1-P
88.3 (68.4–114.5) 81.4 (60.0–107.4) 0.219 91.1 (73.2–119.9) 95.9 (78.3–128.5)# 0.215
 SM(d18:1/12:0) 1102.8 (561.7–1328.7) 1131.0 (615.0–1342.1) 0.066 1495.6 (921.5–1717.5)* 1794.1 (1221.6–2473.0) 0.854









 SM(d18:1/24:4) 1810.8 (1290.7–2388.9) 2426.6 (1756.9–3651.7) 0.040 1389.6 (916.5–2164.5) 1782.6 (1215.9–2228.4) 0.131
Phosphoglyceride (pmol/ml)
 LPC(14:0) 766.1 ± 533.2 508.5 ± 278.9 0.008 777.1 ± 562.5 651.7 ± 344.9# 0.239
 LPC(16:1) 2149.7 (1322.3–2461.9) 1288 (1020–1662) 0.001 1948.2 (1509.1–2438.3) 1567.1 (1097.0–2049.6) 0.021









 LPC(18:1) 21,454.3 (15,067.6–
27,481.6)





 LPC(18:2) 27,509.3 (23,480.1–
35,012.6)





 LPC(18:3) 13,616.8 (11,638.8–
15,873.7)





 LPC(20:0) 240.3 (195.0–2721.8 179.9 (128.8–214.5) 0.003 211.5 (142.3–300.6) 195.2 (147.0–250.7) 0.209
 LPC(20:2) 431.6 (223.3–603.5) 505.6 (324.2–729.5) 0.140 332.2 (273.4–565.4) 538.1 (413.1–763.0) 0.005
 LPC(20:3) 9995.9 ± 3311.8 10,234.2 ± 2985.6 0.733 10,128.2 ± 3877.3 11,989.3 ± 4074.7# 0.031
 LPC(20:4) 10,415.2 (9050.0–12,533.2) 22,367.1 (18,945.2–
27,351.0)
0.000 9537.0 (8019.2–13,176.2) 23,141.1 (18,657.2–
30,853.1)
0.000
 LPC(20:5) 5946.8 (4188.1–6098.2) 7162.1 (6231.0–8515.7) 0.000 5548.6 (4449.0–6600.0) 7380.1 (6296.8–8854.0) 0.000
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More lipids were significantly changed after berberine 
treatment compared with lifestyle intervention. Nineteen 
free fatty acids [FA(15:1), FA(16:1), FA(16:2), FA(16:3), 
FA(18:1), FA(18:2), FA(20:2), FA(20:3), FA(20:4), 
FA(20:5), FA(22:4), FA(22:5), FA(22:6), FA3, FA40, FA48, 
FA51, FA(α-18:3), FA(γ-18:3)] were markedly decreased 
in the BBR group, and 8 of these free fatty acids were 
also altered after lifestyle intervention. Levels of 
Cer(d18:1/18:0), Cer(d18:1/20:0) and Cer(d18:1/18:0)-1P 
sphingolipids were significantly decreased. The sphingo-
myelin (SM) SM(d18:1/16:1) was significantly decreased, 
and SM(d18:1/24:4) was elevated. Levels of LPE(18:0), 
LPE(O-20:0), PC(O-36:3), PC(P-38:5), PC(40:8), PS(P-
36:1), 5 lysophosphatidylcholine [LPC(14:0), LPC(16:1), 
LPC(18:0), LPC(18:3), LPC(20:0)], 3 phosphatidylino-
sitol [PI(34:2), PI(40:6), PS(P-36:1)] and TG(52:7) were 
markedly decreased, and LPI(18:0), LPI(20:4), PC(P-38:5) 
and 4 lysophosphatidylcholines [LPC(18:2), LPC(20:2), 
LPC(20:4), LPC(20:5), LPC(22:6)] were significantly ele-
vated (Table 2).
Table  2 shows that most lipids were markedly 
decreased after LSI. Levels of 8 free fatty acids [FA(16:1), 
The data were presented as the mean ± SD, except for skewed variables, which were presented as the median with the interquartile range given in parentheses. The 
unit of lipids in this table was pmol/mL, except for free fatty acids which were 1
* P < 0.05 when comparing berberine plus lifestyle intervention group and lifestyle intervention alone group at baseline
# P < 0.05 when comparing berberine plus lifestyle intervention group and lifestyle intervention alone group after 16-week treatment
Table 2 continued
BBR plus LSI (n = 41) P value LSI (n = 39) P value
Baseline 16 w Baseline 16 w
 LPC(22:6) 2154.4 (1496.9–2841.6) 4731 (3964–7186) 0.000 2039.1 (1394.3–2047.0) 5763.1 (4396.7–7838.1) 0.000
 LPE(16:0) 575.5 (437.8–733.7) 506.9 (409.4–689.7) 0.688 685.2 (530.7–882.2)* 646.4 (447.8–1000.5) 0.311
 LPE(18:0) 632.9 (434.0–876.8) 322.9 (229.4–417.5) 0.000 682.3 (462.8–955.6) 362.4 (255.5–475.9) 0.000
 LPE(O-20:0) 326.1 ± 150.4 232.3 ± 110.2 0.002 324.5 ± 196.0 283.1 ± 187.0 0.343
LPI(18:0) 286.1 (145.7–426.6) 649.0 (545.0–1019.9) 0.000 266.2 (166.9–538.2) 770.2 (591.7–1063.6) 0.000
 LPI(20:4) 135.1 (8.31–214.0) 642.8 (505.1–772.2) 0.000 156.7 (117.3–238.0) 750.9 (552.6–883.7) 0.000
 LPS(O-18:0) 161.9 (102.2–189.9) 137.1 (111.0–179.0) 0.236 156.6 (79.3–230.5) 84.9 (62.7–126.7) 0.010
 PC(O-36:3) 2406.3 (1419.2–4111.8) 1645.2 (1028.1–2062.1) 0.010 2601.0 (2043.8–3684.2) 1416.1 (978.2–2124.0) 0.000
 PC(34:0) 3277.6 (2676.6–3817.9) 2862.6 (2007.3–3850.8) 0.525 2615.7 (1906.1–3682.2)* 2662.1 (2300.6–3108.3) 0.128


















 PC(P-38:5) 1997.1 (1525.7–3132.2) 1076.7 (545.6–1717.7) 0.000 1868.1 (1443.7–2673.1) 834.8 (584.1–1232.5) 0.000
 PC(40:5) 4708.1 (2919.5–6161.2) 4472.5 (2727.7–7600.9) 0.694 3020.5 (1615.0–5141.7)* 3764.6 (2770.9–4453.6) 0.267
 PC(40:8) 5548.6 (3987.5–8139.5) 4550.1 (2762.6–6087.2) 0.048 5139.6 (3316.1–6483.0) 4002.0 (3025.1–5229.7) 0.213
 PC(40:9) 1262.7 (704.9–1563.1) 1222.2 (831.9–1621.9) 0.861 1022.2 (766.7–1213.7) 770.0 (549.5–1103.0) 0.073
 PI(34:2) 5696.3 (3559.2–11,738.2) 3535 (2142–6030) 0.008 7266.5 (3857.6–14,957.1) 4547.6 (1833.0–10,994.1) 0.033
 PI(36:2) 5850.2 (4289.3–8214.6) 5376.2 (3834.7–7459.8) 0.328 6546.3 (4829.2–8008.2) 4412.7 (3257.6–6519.1) 0.010
 PI(36:3) 1196.8 (774.1–1642.2) 929.8 (732.7–1315.8) 0.212 1156.7 (863.7–1461.1) 867.2 (592.8–1153.4) 0.034
 PI(36:4) 13,953.2 (4650.9–25,982.1) 5958.3 (3447.4–15,387.2) 0.040 13,822.2 (5681.0–
29,772.2)
7950.0 (3106.8–24,503.1) 0.225









 PI(38:6) 2417.7 (1479.4–48,710.8) 1712.3 (1181.8–3517.3) 0.073 3413.8 (2439.5–5993.4) 2308.4 (1689.1–3363.4) 0.014
 PI(40:6) 794.9 (589.5–1326.9) 543.3 (421.2–829.7) 0.003 932.1 (680.0–1457.6) 646.1 (489.2–1081.1) 0.016
 PS(P-36:1) 4455.3 (2066.7–7302.3) 2056.2 (1040.2–3618.7) 0.003 3341.2 (2557.0–5854.9) 2351.0 (1410.1–3852.2) 0.021
Triglyceride (pmol/ml)
 TG(46:11) 247.4 (132.5–668.7) 121.2 (87.3–418.6) 0.216 219.2 (156.8–517.2) 194.1 (89.2–284.2) 0.005
 TG(48:0) 290.9 (117.6–594.5) 250.8 (83.1–535.7) 0.068 482.4 (135.7–1054.5) 463.8 (103.9–1081.2)# 0.199
 TG(P-52:1) 26.5 (18.8–56.7) 27.7 (14.7–40.9) 0.919 42.0 (25.7–66.0) 42.8 (22.5–65.5)# 0.618
 TG(52:7) 275.6 (148.7–418.7) 215.2 (128.7–335.2) 0.007 320.1 (154.0–762.8) 311.2 (172.1–518.0)# 0.116
 TG(54:8) 711.3 (419.8–1176.3) 579.2 (284.1–909.1) 0.053 937.5 (433.3–2118.2) 913.9 (433.4–1363.6)# 0.074
Page 7 of 11Chang et al. J Transl Med  (2016) 14:266 
FA(16:2), FA(18:2), FA(20:2), FA(20:3), FA27, FA51, 
FA(α-18:3)] were significantly decreased. The levels of 
LPC(16:1), LPC(18:3), LPE(18:0), LPS(O-18:0), PC(O-
36:3), PC(P-38:5) and 6 phosphatidylinositols [PI(34:2), 
PI(36:2), PI(36:3), PI(38:4), PI(38:6), PI(40:6)], PS(P-36:1) 
were significantly decreased, and LPI(18:0), LPI(20:4) 
and 7 lysophosphatidylcholine [LPC(18:1), LPC(18:2), 
LPC(20:2), LPC(20:3), LPC(20:4), LPC(20:5), LPC(22:6)] 
levels were markedly elevated. The TG (46:11) level was 
also significantly decreased.
Only 5 lipids were significantly different before BBR treat-
ment or LSI: LPE (16:0), PC(34:0), PC(38:4), PC(40:5) and 
SM(d18:1/12:0). However, 10 lipids were markedly different 
after the two interventions. Levels of Cer(d18:1/28:0)-1-P, 
LPC(14:0), LPC(20:3) and 4 triglycerides [TG(48:0), TG(P-
52:1), TG(52:7), TG(54:8)] in the berberine treatment group 
were significantly lower than the lifestyle intervention 
group. Levels of SM(d18:1/24:4), PC(36:4) and PC(40:9) 
in the berberine treatment group were significantly higher 
than the lifestyle intervention group.
These results demonstrated that the lipid-lowering 
effect of berberine was similar with lifestyle interven-
tion. Both treatments regulated various types of lipids 
in metabolic pathways. The two interventions similarly 
regulated free fatty acids, phosphoglycerides and glyc-
erides, but there were obvious differences in regulation 
for sphingolipids. Ceramide and ceramide-1-phosphate 
levels decreased markedly after BBR treatment, and 
sphingomyelin levels were slightly elevated. The lifestyle 
intervention only significantly decreased sphingosine 
levels. These data suggest that berberine participates in 
phospholipid metabolism.
Orthogonal partial least squares discriminant analysis 
(OPLS-DA) was used to further study the subtle differ-
ences between groups. Figure  2 shows the score plots 
obtained from OPLS-DA. Patient groups before and after 
lifestyle intervention exhibited a reliable discrimination, 
which means lifestyle intervention obviously affected 
lipid metabolic pathways. OPLS-DA analysis detected 
four biomarkers that reflected the therapeutic effect of 
lifestyle intervention (Table 3).
The berberine treatment group also exhibited an 
obvious discrimination, which means that berberine 
markedly regulated the lipid metabolic pathways. Six bio-
markers that reflected the therapeutic effect of berberine 
were detected (Table 3).
The two groups of patients could not be discrimi-
nated before intervention. The two groups only achieved 
incomplete discrimination after intervention. Only two 
biomarkers were detected that discriminated these two 
types of intervention (Table 3).
Discussion
In the present study, BBR treatment for 16 weeks reduced 
more hepatic fat content in NAFLD patients, which was 
paralleled with a global metabolic benefit, as reflected 
Fig. 1 Lipid metabolic pathways and the regulation of berberine on the patients with IGR/Type 2 diabetes and nonalcoholic fatty liver disease
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in reduced body weight and improved glucose and lipid 
profiles compared with lifestyle intervention alone. Lipid-
omics analyses demonstrated that berberine and lifestyle 
intervention alone regulated various types of lipids in 
lipid metabolic pathways comprehensively. Notably, ber-
berine exerted a special effect on sphingolipids, including 
a down-regulation of ceramides, which play an important 
role in the pathogenesis of nonalcoholic fatty liver dis-
ease. However, lifestyle intervention alone had no effect 
on ceramides.
Patients treated with berberine lost significantly more 
liver fat content and exhibited greater reductions in 
blood glucose, triglycerides and cholesterol than the LSI 
group, which is consistent with previous studies [1, 2, 
7]. BBR was absorbable after oral administration in our 
previous study [9], which demonstrated that BBR directly 
affected hepatic lipid metabolism.
Previous studies indicated that fat deposit in hepato-
cytes was associated with several changes in circulating 
lipidomes [11]. Lipids are the fundamental components 
of cellular membranes, and they are essential because 
they represent the biochemical activity signature dur-
ing lipid metabolism. Therefore, lipids are closely related 
to observable phenotypes. Lipidomics is the process of 
defining multivariate lipid metabolic trajectories that 
represent the systemic response (i.e., holistic lipid meta-
bolic changes) of a living system to pharmaceutical inter-
ventions over time.
Fig. 2 In order to further study the subtle differences between groups, orthogonal partial least squares discriminant analysis (OPLS-DA) was 
employed. This figure was the score plots obtained from OPLS-DA
Table 3 Lipid biomarkers found in patients’ plasma
Based on the criteria for the identification of the potential biomarkers, OPLS-DA 
analysis detected some biomarkers reflecting the therapeutic effect of berberine 
and lifestyle intervention
Before LIS vs. 
after LIS
Before BBR plus LIS vs. 
after BBR plus LIS
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Berberine plus lifestyle intervention and lifestyle inter-
ventional one exhibited a substantially greater effect 
on serum lipid metabolism, which primarily included 
FA, LPC, LPI, LPE, PC and PI (Table 2). Only berberine 
plus lifestyle intervention altered serum sphingolipids, 
including decreasing serum sph(d18:1), Cer(d18:1/18:0), 
Cer(d18:1/18:0)-1-p, and Cer(d18:1/20:0) levels, which 
was not achieved by exercise with diet control alone. This 
effect may be a special mechanism of berberine.
Ceramides are important members of the sphingolipid 
family, and they are essential precursors for complex 
sphingolipids. Ceramide and ceramide-derived sphin-
golipids are structural components of membranes, and 
these components are associated with insulin resistance, 
oxidative stress, and inflammation [17–19], which suggest 
that they play a role in the development of liver steatosis 
[20, 21]. Ceramides (Cer) may inhibit several mediators 
of the insulin signaling pathway, including insulin recep-
tor substrate 1 (IRS1), phosphatidylinositol 3-kinase 
(PI-3  K) and AKt/PKB [22]. Previous studies indicated 
that inhibition of ceramide synthesis, including cera-
mide-1-phosphate and glucosylceramide, inhibited sev-
eral underlying causes of insulin resistance and improved 
insulin sensitivity in tissues [23–26]. A recent report 
suggested that the liver is a major contributor of circu-
lating ceramide species [21]. Plasma levels of total cera-
mide and all ceramide species in western-diet induced 
NAFLD were elevated, and major changes were observed 
in Cer(d18:1/16:0), Cer(d18:1/22:0), Cer(d18:1/24:0) and 
Cer(d18:1/24:1). A study in animals demonstrated that 
inhibition of ceramide biosynthesis reduced hepatic 
and plasma ceramides and sphingomyelin, improved 
insulin sensitivity and reduced hepatic fat accumula-
tion [27, 28]. Berberine significantly decreased the level 
of ceramides in the present study, with major changes in 
Cer(d18:1/18:0), Cer(d18:1/20:0) and Cer(d18:1/18:0)-1P, 
which demonstrates that the improving effects of BBR in 
liver steatosis related to ceramide reduction.
Berberine also reduced blood glucose levels in the oral 
glucose tolerance test (OGTT), which is consistent with 
previous studies [7]. Some studies suggested that berber-
ine decreased blood glucose by improving insulin resist-
ance [7]. A recent report suggested that overexpression 
of acid ceramidase in the liver reduced hepatic ceramide 
levels and improved hepatic and adipose insulin sensi-
tivity [21]. Plasma ceramide levels reflected changes in 
hepatic ceramide levels. The present study found that 
berberine reduced circulating ceramide levels, which 
may be related to decreasing serum glucose.
Lipid microdomains or caveolae, which are small 
invaginations of plasma membrane, emerged as 
important elements for lipid uptake, including triglyc-
erides (TG) and fatty acids [29]. Sphingomyelin (SM) 
is a major phospholipid of lipid microdomains. The 
conversion of SM to Cer is also necessary to maintain 
the homeostasis of these domains [30]. Sphingomy-
elin synthase (SMS) converts Cer to SM in the plasma 
membrane, and a deficiency of SMS may affect the 
metabolism of ceramide, sphingosine and sphingosine 
1-phosphate. The present study found that berberine 
also altered plasma levels of SM, as characterized by a 
significant decrease in SM(d18:1/16:1) and elevated 
SM(d18:1/12:0) and SM(d18:1/24:4).BBR also reduced 
the level of ceramides. However, how these changes 
affect hepatic fat deposit requires investigation.
PC combats fatty liver and blood lipid disorders due to 
obesity [31, 32], promotes the absorption and utilization 
of lipid, removes cholesterol from vessel walls, reduces 
HDL-cholesterol and promotes hydrolysis of athero-
sclerotic plaques [33]. The content ratio of PC and PE is 
closely related to the accumulation of TG in liver [34]. 
Berberine treatment and lifestyle intervention regulated 
the level of PC in plasma. Two PCs containing polyunsat-
urated fatty acids [PC(36:4) and PC(40:9)] were biomark-
ers that discriminated between these two interventions, 
and the levels of these PCs in the berberine group were 
significantly higher than the lifestyle intervention.
Lysophosphatidylcholine (LPC) has been reported 
to be closely related to many inflammatory diseases, 
such as T2DM, obesity, and atherosclerosis [35]. Several 
LPC biomarkers [LPC(18:2), LPC(20:4), LPC(20:5), and 
LPC(22:6)] were significantly elevated after BBR treat-
ment, and other LPCs [LPC(14:0), LPC(16:1), LPC(18:0), 
LPC(18:3), and LPC(20:0)] were reduced. Lifestyle inter-
vention also caused similar changes. The levels of 2 
lysophosphatidylinositol (LPI) biomarkers [LPI(18:0) and 
LPI(20:4)] also markedly increased after berberine and 
lifestyle intervention alone treatments. The role of this 
lipid type has not been reported in type 2 diabetes or 
nonalcoholic fatty liver disease.
Further studies are needed to elucidate the biological 
mechanisms accounting for the link between berberine, 
serum lipid profile, especially ceramides, and fatty liver, 
but these findings indicate that the systematic analysis of 
serum lipid species, rather than lipid classes as a whole, 
may reveal the beneficial effects of berberine on fatty 
liver beyond improvements in clinical biomarkers.
One limitation of the present study is the cross-sec-
tional nature of the study, and no patients were examined 
using liver biopsy because of ethical concerns. Therefore, 
the effects of BBR on human hepatic lipid profile and the 
genes related to lipid metabolism require further study.
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Conclusions
The application of LC-MS-based lipidomics and meas-
urement of biochemical parameters revealed the differ-
ential therapeutic effects of berberine and mere lifestyle 
intervention on serum lipid profile, which were compa-
rable with their differential effects on hepatic fat content, 
serum lipid and glucose metabolism. Berberine more 
substantially altered serum lipid species compared with 
mere lifestyle intervention. The altering of sphingolipid 
metabolism by BBR, including a decrease in serum cer-
amides, was a novel mechanism. These findings suggest 
that a lipidomics approaches useful for the elucidation of 
the complex mechanism of action of particular drugs and 
a novel tool to probe the mechanisms of NAFLD progres-
sion. Future studies are required to precisely evaluate 
the predictive findings in additional cohorts and confirm 
whether we identified an early marker of NAFLD and its 
associated therapeutics.
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